A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”

(2016) Lavinia Spain et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

(2016) Elizabeth Hansen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient

(2016) Yukiko Teramoto et al.   JOURNAL OF DERMATOLOGY

Genetic risk factors for type 1 diabetes

(2016) Flemming Pociot et al.   LANCET

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

(2016) Yuka Miyoshi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma

(2015) N. Yamazaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

(2015) Juan Martin-Liberal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes

(2015) R. Fujisawa et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

(2015) Caroline Gaudy et al.   DIABETES CARE

Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus

(2015) Valentina Perri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes

(2014) Nora M. Kochupurakkal et al.   PLoS One

Ipilimumab-induced autoimmune adrenalitis

(2013) Le Min et al.   Lancet Diabetes & Endocrinology

New-Onset Type 1 Diabetes Mellitus and Anti-Aquaporin-4 Antibody Positive Optic Neuritis Associated with Type 1 Interferon Therapy for Chronic Hepatitis C

(2012) Tomoya Kawazoe et al.   INTERNAL MEDICINE

The role of interferon alpha in initiation of type I diabetes in the NOD mouse

(2011) Qing Li et al.   CLINICAL IMMUNOLOGY

Genetics of the HLA Region in the Prediction of Type 1 Diabetes

(2011) Janelle A. Noble et al.   Current Diabetes Reports

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

(2010) Le Min et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Distinct Clinical Courses in Type 1 Diabetes Mellitus Induced by Peg-interferon-α Treatment for Chronic Hepatitis C

(2010) Masanori Yamazaki et al.   INTERNAL MEDICINE

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes

(2009)   DIABETES CARE

Interferon-  initiates type 1 diabetes in nonobese diabetic mice

(2008) Q. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B

(2008) Yuan-Yuan Lv et al.   WORLD JOURNAL OF GASTROENTEROLOGY